Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002
← catalyst calendarNCT06262399 · readout ≤ 5,003 d
Sponsored by Intellia Therapeutics (industry) · NTLA — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
100estimated
Sites
7
Countries
Australia, France, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-12 | actual | When the study began enrolling |
| Primary completion | Apr 2040 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2040 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hereditary Angioedema
Primary outcome
what the primary-completion date above is the date OFIncidence of treatment-related Adverse Events (AEs); incidence of treatment-related Serious Adverse Events (SAEs); incidence of treatment-related Adverse Events of Special Interest (AESIs) defined per protocol
measured up to 15 years
Permalink · NTLA's whole pipeline · Catalyst calendar · Every registered study · What changed